NEUROPACE, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M | $41.1M |
| Cost of Revenue | — | $22.8M | $20.8M | $17.3M | $13.0M | $11.7M | $10.9M |
| Gross Profit | — | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M | $30.3M |
| Gross Margin | — | 77.2% | 73.9% | 73.6% | 71.4% | 74.0% | 73.6% |
| Operating Expenses | |||||||
| Research & Development | — | $27.9M | $23.7M | $20.8M | $21.9M | $18.2M | $15.7M |
| SG&A Expense | — | $19.1M | $57.1M | $54.5M | $51.3M | $39.0M | $27.6M |
| Operating Income | — | $-16.3M | $-21.7M | $-27.2M | $-40.8M | $-23.7M | $-13.1M |
| Operating Margin | — | -16.3% | -27.1% | -41.5% | -89.6% | -52.5% | -31.7% |
| Interest Expense | — | — | — | $8.5M | $7.5M | $7.4M | $11.5M |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | — | — | — | — | — |
| Net Income | — | $-21.5M | $-27.1M | $-33.0M | $-47.1M | $-36.1M | $-24.3M |
| Net Margin | — | -21.5% | -34.0% | -50.4% | -103.4% | -79.9% | -59.0% |
| EPS (Basic) | — | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 | $-1.45 |
| EPS (Diluted) | — | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 | $-1.45 |
| Shares Outstanding (Basic) | 33.7M | 32.7M | 29.1M | 25.9M | 24.6M | 16.6M | 16.5M |
| Shares Outstanding (Diluted) | 33.7M | 32.7M | 29.1M | 25.9M | 24.6M | 16.6M | 16.5M |
| Dividends Per Share | — | $0.00 | $0.00 | $0.00 | — | — | — |